Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults

NCT ID: NCT05055882

Last Updated: 2024-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, evanescent rash and arthritis. Although it is benign in the vast majority of cases, life-threatening complications can occur. By definition, the disease affects adults over 16 years of age, however most experts now agree that the adult form and the pediatric form belong to a pathological continuum: Still's disease. In the absence of a specific biomarker, the diagnosis is still based on clinical and biological criteria, after the exclusion of differential diagnoses.

Classically, three evolutionary profiles of Adult-Onset Still's disease are individualized, depending on the evolution of symptoms over time:

* a monocyclic systemic form (30% of cases) characterized by clear systemic symptoms and in the foreground compared to the articular signs. This form evolves over several weeks to several months (on average 9 months), without exceeding a year. By definition, there is no recurrence;
* a polycyclic systemic form (30% of cases) defined by the occurrence of at least two systemic or joint episodes, separated by clinical remission intervals greater than two months, or even several years. The symptoms of relapses are not always the same as the initial symptoms. The number and severity of relapses is unpredictable and varies widely from patient to patient, but symptoms tend to become less severe over time.
* a chronic form, with predominant joint involvement (40%), resembling seronegative rheumatoid arthritis. Systemic signs are present during the first outbreaks of the disease. Subsequently, rheumatoid arthritis evolves on its own and one can see joint destruction or conversely ankylosing developments such as the classic bilateral, non-erosive fusing carpitis.

There are reasons to believe that the evolving profile of patients has changed since the emergence and generalization of biotherapies. Furthermore, no prognostic factor for the progression of Adult-Onset Still's disease has been found so far. The differences between pediatric and adult forms need to be confirmed and becoming pediatric forms in adulthood is poorly described.

The objective of this study is to set up a regional research database (Auvergne-Rhône-Alpes-Limousin) in order to describe the characteristics, treatment and evolution of patients with Still's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Still Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

Intervention Type OTHER

Comparison of Adult-Onset Still's disease phenotypes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

Comparison of Adult-Onset Still's disease phenotypes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

Exclusion Criteria

* Not applicable
Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital de la Croix Rousse

Lyon, Auvergne-Rhône-Alpes, France

Site Status RECRUITING

Centre Hospitalier de Valence

Valence, Drome, France

Site Status RECRUITING

Centre Hospitalier d'Annecy

Annecy, , France

Site Status RECRUITING

Centre Hospitalier de Bourg en Bresse

Bourg-en-Bresse, , France

Site Status RECRUITING

Centre Hospitalier Bourgoin Jallieu

Bourgoin, , France

Site Status RECRUITING

Centre Hospitalier de Chambéry

Chambéry, , France

Site Status RECRUITING

Centre Hospitalier de Châlon sur Saône

Châlon Sur Saône, , France

Site Status RECRUITING

Centre Hospitalier Alpes-Léman (CHAL)

Contamine-sur-Arve, , France

Site Status RECRUITING

Centre Hospitalier du puy en velay

Le Puy-en-Velay, , France

Site Status RECRUITING

Centre Hospitalier de Limoges

Limoges, , France

Site Status RECRUITING

Hopital Saint Luc Saint Joseph

Lyon, , France

Site Status RECRUITING

Hospices Civils de Lyon - Edouard Herriot

Lyon, , France

Site Status RECRUITING

Centre Hospitalier de Montélimar

Montélimar, , France

Site Status RECRUITING

Centre Hospitalier Vienne

Vienne, , France

Site Status RECRUITING

Centre Hospitalier de Villefranche

Villefranche-sur-Saône, , France

Site Status RECRUITING

Médipôle de Villeurbanne

Villeurbanne, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yvan Jamilloux, Dr

Role: CONTACT

+33426732636

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yvan Jamilloux, Dr

Role: primary

+33426732636

Thierry Zenone, Dr

Role: primary

+33475757274

Alice Bérezné, Dr

Role: primary

Pascal Sève

Role: primary

+33426732636

Marielle Roux, Dr

Role: primary

+33469157329

Emmanuel Forestier, Dr

Role: primary

+33473965050

Eric Monard, Dr

Role: primary

+33385446688

Jason Hubac, Dr

Role: primary

+33450823022

Julie Planchette, Dr

Role: primary

+33471043463

Eric Liozon, Dr

Role: primary

+33555056990

Stéphane Martinon, Dr

Role: primary

+33478618329

Arnaud Hot

Role: primary

+33472117565

Ahmed Azzedine, Dr

Role: primary

+33475534429

Leopold Adelaide, Dr

Role: primary

+33474313355

Julie Le Scanff, Dr

Role: primary

+33474092929

Bertrand Issartel, Dr

Role: primary

+33472823400

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRC_GHN_2021_003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biomarkers in Giant Cells Arteritis
NCT02844023 TERMINATED NA